AbbVie Bets Up to $2.54B on Disco's Next-Gen Cancer Drugs
AbbVie is teaming up with Germany's Disco Pharmaceuticals on bispecific cancer therapies, paying $40 million upfront and dangling up to $2.5 billion in milestones. The deal, announced Thursday, pushes the drugmaker deeper into next-generation treatments for solid tumors.
- Original source: reuters.com.
- No second outlet has reported it yet. Treat it as a single-source claim.
- The source shows no publish time. The time above is when we found it.
AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said Thursday. The structure: $40 million upfront, plus up to $2.5 billion tied to milestone payments.
The partnership targets so-called AND-gated bispecific therapeutics for solid tumors — an early-stage bet by AbbVie on next-generation bispecific therapies. Disco has been developing those AND-gated treatments for small-cell lung and colorectal cancer.
Disco CEO Mark Manfredi said his company will handle the research and discovery work. AbbVie, in turn, gets the right to exclusively license selected programs for further development.
Manfredi said Disco expects to pick a development candidate in the second half of next year, the next concrete checkpoint for the collaboration.
TopicsAbbVie · Disco Pharmaceuticals · Mark Manfredi
Source: reuters.com
Written by AI from verified reporting.
More stories
- Health & science finance.yahoo.com 0 viewsSanofi's next-gen rabies shot VaxRabeo scores EU approval
- Health & science fnob.it 1 viewTenK10K maps 5 million immune cells, linking DNA variants to 16 diseases
- Health & science trtworld.com Caught by @pz09253 0 viewsFrance lifts bird flu alert to maximum level across mainland
- Health & science news24.com.au 0 viewsActinogen trial: Alzheimer's drug slows decline by 30pc in over-75s

